Column Capital Advisors’s AstraZeneca AZN Stock Holding History

Column Capital Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$19.4K	Hold	143	–	–	﹤0.01%	438
2023 Q2	$20.5K	Hold	143	–	–	﹤0.01%	436
2023 Q1	$19.9K	Hold	143	–	–	﹤0.01%	446
2022 Q4	$19.4K	Hold	143	–	–	﹤0.01%	423
2022 Q3	$16K	Sell	143 -11	-7%	-$1.4K	﹤0.01%	412
2022 Q2	$20K	Hold	154	–	–	﹤0.01%	384
2022 Q1	$20K	Sell	154 -15	-9%	-$1.8K	﹤0.01%	406
2021 Q4	$20K	Buy	169 +26	+18%	+$3.06K	﹤0.01%	408
2021 Q3	$17K	Buy	143 +24	+20%	+$2.79K	﹤0.01%	399
2021 Q2	$14K	Hold	119	–	–	﹤0.01%	423
2021 Q1	$12K	Hold	119	–	–	﹤0.01%	431
2020 Q4	$12K	Hold	119	–	–	﹤0.01%	434
2020 Q3	$13K	Sell	119 -147	-55%	-$16.4K	﹤0.01%	402
2020 Q2	$28K	Buy	266 +179	+206%	+$18.5K	0.01%	327
2020 Q1	$8K	Buy	87 +13	+18%	+$1.22K	﹤0.01%	418
2019 Q4	$7K	Buy	+74	New	+$6.97K	﹤0.01%	484

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Column Capital Advisors's AZN Position: Q3 2023 in Review

Column Capital Advisors held its AstraZeneca (AZN) position steady in Q3 2023 at 143 shares worth $19.4K. The position accounts for ﹤0.01% of the portfolio, ranked #438.

Column Capital Advisors first reported a position in AZN in Q4 2019 and has held it in 16 quarters since. The position peaked at $28K in Q2 2020. 1,073 funds tracked by Wall St. Rank hold AZN as of Q3 2023.

Column Capital Advisors held 143 shares of AstraZeneca worth $19.4K as of Q3 2023.
Column Capital Advisors left its AstraZeneca share count unchanged in Q3 2023.
AstraZeneca made up ﹤0.01% of Column Capital Advisors's portfolio in Q3 2023, its #438 holding.
Column Capital Advisors first reported a position in AstraZeneca in Q4 2019 and has held it in 16 quarters since.
Column Capital Advisors's AstraZeneca position peaked at $28K in Q2 2020.
1,073 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2023.

Based on Column Capital Advisors's 13F filing for Q3 2023, filed 3 Nov 2023.